Shannon Connelly

Michael A. Morse, MD, recently discussed treatment decisions centered around the care of patients with metastatic colorectal cancer. Morse, professor of Medicine, Duke Cancer Institute, explained his treatment decisions in 2 case scenarios during a&nbsp;<em>Targeted Oncology</em>&nbsp;live case-based peer perspectives dinner.

Paul A. Bunn, MD, discusses why pseudoprogression and hyperprogression are concerns when treating patients with immunotherapy, and weighed in on what to do in each situation.

The 2017 ESMO Annual Congress, taking place September 8 to 12 in Madrid, Spain, will feature several late-breaking abstracts that are poised to change the future of treatment for patients with lung cancer, pending their results, including the&nbsp;phase III PACIFIC and FLAURA studies.

Omid Hamid, MD, shares&nbsp;the top melanoma abstracts to look out for at the 2017 ESMO Annual Congress, which is taking place September 8 to 12 in Madrid, Spain, as well as some background on the promising phase I/II results he will be presenting for the combination of epacadostat plus pembrolizumab in patients with advanced melanoma.

Frankie Ann Holmes, MD, discusses which breast cancer patients can benefit from endocrine therapy and the challenges that still exist with deciding between chemotherapy and endocrine therapy for each patient.

Tissue samples will continue to be necessary in the practice of immunotherapy as more biomarkers for cancer become known, and solid biopsies remain the prime means of assessing the presence of cancer, says Ignacio I. Wistuba, MD.

Sacituzumab govitecan (IMMU-132) was well tolerated and demonstrated early and durable responses in heavily pretreated patients with metastatic triple-negative breast cancer (mTNBC), according to the results of a recent phase I/II study published in the <em>Journal of Clinical Oncology</em>.<br /> &nbsp;

Lisa Carey, MD, discusses&nbsp;strategies that can be used to de-escalate treatment in patients with triple-negative breast cancer and the steps toward developing further strategies in this area.

Keith Stewart, MB, ChB, discusses treatment decisions centered around the care of patients with multiple myeloma, including the roles of autologous stem cell transplant and MRD testing.

Arlene Siefker-Radtke, MD, discusses&nbsp;the current status of biomarker research in bladder cancer, and the impact immunotherapy has had in the field.

Jonathan C. Trent, MD, PhD, recently discussed the treatment considerations he makes when treating patients with gastrointestinal stromal tumors (GIST). Trent discussed his treatment decisions based on 2 case scenarios during a&nbsp;<em>Targeted Oncology</em>&nbsp;live case-based peer perspectives dinner.

Mark Pegram, MD, shares some of the most recent developments in the HER2-positive metastatic breast cancer space, the research currently ongoing, and why it is such an exciting time for the field.

In an interview with <em>Targeted Oncology,&nbsp;</em>Arti Hurria, MD,&nbsp;shares the treatment considerations she makes when treating older patients with breast cancer, the unique challenges that come with treating this patient population, and the exciting future she envisions for this space.

Michael B. Atkins, MD, recently shared treatment considerations he would make when treating patients with metastatic renal cell carcinoma (RCC), based on 2 case scenarios.

Christophe Massard, MD, PhD, discusses ongoing clinical trials evaluating durvalumab, toxicities to be aware of with the agent, and the impact the approval has had in the field.

Current guidelines recommend waiting 6 months before resecting a large hepatocellular adenoma to prevent a transformation to a malignant tumor; however, a recent study suggests that waiting longer could benefit some patients.

Pam Profusek, RN, MS, discusses&nbsp;how to manage the AEs associated with immunotherapy agents, like durvalumab.

Martin Dreyling, MD, discusses results of the&nbsp;phase II CHRONOS-1 study&nbsp;in patients with relapsed or refractory indolent B-cell lymphoma.

Richard M. Stone, MD,&nbsp;discusses the impact that midostaurin could have for patients with AML, as well as ongoing research with the agent.

Wassim Abida, MD, PhD, discusses&nbsp;how genetic testing can benefit patients with prostate cancer and their families, and the challenges that still need to be addressed in this area.

Christian G. Downs, JD, MHA, discusses&nbsp;his thoughts on how rebuilding the 340B program should be addressed, Medicare Payment Advisory Commission&rsquo;s Part B cost control proposals, and the potential for progress in tackling rising drug costs.

Leah Ralph discusses&nbsp;the ACCC&rsquo;s position on the ACA repeal bill, the Medicare Payment Advisory Commission&rsquo;s (MedPAC) Part B cost control proposals, and the possibility for comprehensive reform on the 340B Drug Discount Program.

Joshua Armenia, PhD, discusses an analysis that uncovered 23 genes that have not been previously identified as significantly mutated in prostate cancer.

Dana Chase, MD, discusses&nbsp;the potential for immunotherapy in recurrent endometrial cancer, as well as the lack of progress made thus far in endometrial cancer and other rare cancer types.

Matthew B. Yurgelun, MD, discusses a colorectal cancer study which found nearly 10% of the individuals had an inherited mutation in a cancer susceptibility gene.

Leonard Gomella, MD, discusses the future of biomarkers in prostate cancer.

Julie R. Brahmer, MD, discusses&nbsp;5-year follow-up data from the CA209-003 study of nivolumab for patients with metastatic non&ndash;small cell lung cancer.

Andrew Wei, MBBS, PhD, discusses&nbsp;a study which explored the safety and efficacy of the novel BCL-2 inhibitor venetoclax in combination with low-dose cytarabine chemotherapy for treatment-na&iuml;ve patients over the age of 65 with AML.

Steven H. Lin, MD, PhD, discusses&nbsp;the benefits of advanced radiation technologies, including IMRT and proton therapy.

Harry P. Erba, MD, PhD, recently shared treatment considerations he would make when treating patients with polycythemia vera (PV) based on 3 case scenarios.